We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Growing European Demand for Mad Cow Test

By HospiMedica staff writers
Posted on 29 Jan 2001
U.S. More...
company Bio-Rad Laboratories (Hercules, CA) has become a leading provider of tests for bovine spongiform encephalopathy (BSE) in Europe. The company reports it has received orders for more than one million enzyme-linked immunosorbent assays (ELISA) for BSE, known as mad cow disease.

Since October 2000, the fear of BSE has spread quickly throughout Europe, as more cattle were found with the disease. Cows with BSE have been discovered in France, Germany, Spain, Portugal, and Italy. On January 1, 2001, the countries of the European Union commenced mandatory testing of all beef livestock over the age of 30 months in order to insure the highest quality and safety of the European food chain. According to media reports, seven million cattle will have to be tested in Europe this year.

Called Platelia, Bio-Rad's test was selected by the European Commission (EC) as one of the three most sensitive BSE tests and is among the three approved in the most recent EC report. Two independent reports commissioned by a directorate of the EC further substantiated Bio-Rad's test as the preferred test for diagnosing BSE in European cattle. The test is in a screening format for use in high throughput environments, providing results in about four hours.

To meet the demand for tests, Bio-Rad has increased manufacturing capabilities at its French facilities and is mobilizing employees around the world to support the scaling up of production. "We have allocated substantial resources to ensure that we can rapidly meet the growing needs for a quick, clear, and accurate test,” said David Schwartz, president and CEO of Bio-Rad.



Related Links:
Bio-Rad

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.